212 related articles for article (PubMed ID: 25760299)
21. Anti-interleukin-6 therapy in rheumatoid arthritis.
Woodrick R; Ruderman EM
Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
[TBL] [Abstract][Full Text] [Related]
22. [How I treat...rheumatoid arthritis. The arrival of a new therapeutic era: anti-tumor necrosis factor alpha antibodies].
Kaiser MJ; Malaise MG
Rev Med Liege; 2002 Aug; 57(8):486-92. PubMed ID: 12405019
[TBL] [Abstract][Full Text] [Related]
23. Biological response modifiers in the management of rheumatoid arthritis.
Louie SG; Park B; Yoon H
Am J Health Syst Pharm; 2003 Feb; 60(4):346-55. PubMed ID: 12625216
[TBL] [Abstract][Full Text] [Related]
24. Bone effects of biologic drugs in rheumatoid arthritis.
Corrado A; Neve A; Maruotti N; Cantatore FP
Clin Dev Immunol; 2013; 2013():945945. PubMed ID: 23864880
[TBL] [Abstract][Full Text] [Related]
25. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
Cohen SB
Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
[TBL] [Abstract][Full Text] [Related]
26. Relative expression and correlation of tumor necrosis factor-α, interferon-γ, and interleukin-17 in the rheumatoid synovium.
Nakajima A; Aoki Y; Sonobe M; Watanabe F; Takahashi H; Saito M; Nakagawa K
Clin Rheumatol; 2016 Jul; 35(7):1691-7. PubMed ID: 27038187
[TBL] [Abstract][Full Text] [Related]
27. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Change in immune phenotype by the treatment of rheumatoid arthritis.].
Nakayamada S; Tanaka Y
Clin Calcium; 2018; 28(5):619-625. PubMed ID: 29731455
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
Choy E
Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
[TBL] [Abstract][Full Text] [Related]
29. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
30. One-year inhibition of tumor necrosis factor-alpha: a major success or a larger puzzle?
Graninger WB; Smolen JS
Curr Opin Rheumatol; 2001 May; 13(3):209-13. PubMed ID: 11333350
[TBL] [Abstract][Full Text] [Related]
31. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
Park HJ; Ranganathan P
Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.
Timlin H; Bingham CO
Expert Opin Biol Ther; 2014 Jul; 14(7):893-904. PubMed ID: 24720727
[TBL] [Abstract][Full Text] [Related]
33. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
34. The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis.
Paleolog E
Expert Opin Investig Drugs; 2003 Jul; 12(7):1087-95. PubMed ID: 12831345
[TBL] [Abstract][Full Text] [Related]
35. Anti-cytokine therapy for rheumatoid arthritis.
Maini RN; Taylor PC
Annu Rev Med; 2000; 51():207-29. PubMed ID: 10774461
[TBL] [Abstract][Full Text] [Related]
36. Traditional and modern management strategies for rheumatoid arthritis.
Akram M; Daniyal M; Sultana S; Owais A; Akhtar N; Zahid R; Said F; Bouyahya A; Ponomarev E; Ali Shariat M; Thiruvengadam M
Clin Chim Acta; 2021 Jan; 512():142-155. PubMed ID: 33186593
[TBL] [Abstract][Full Text] [Related]
37. Biological agents in rheumatoid arthritis.
Shankar S; Handa R
J Postgrad Med; 2004; 50(4):293-9. PubMed ID: 15623977
[TBL] [Abstract][Full Text] [Related]
38. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
[TBL] [Abstract][Full Text] [Related]
39. [Mechanism of action of biological disease--modifying antirheumatic drugs].
Takahashi N; Ishiguro N
Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
[No Abstract] [Full Text] [Related]
40. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs.
Semerano L; Thiolat A; Minichiello E; Clavel G; Bessis N; Boissier MC
Expert Opin Investig Drugs; 2014 Jul; 23(7):979-99. PubMed ID: 24766460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
